Markets:

Overview

News

Currencies

International

Treasuries

CRISPR Therapeutics AG - Common Shares (NQ:CRSP)

47.99 -0.45 (-0.93%)

Streaming Delayed Price Updated: 4:00 PM EDT, Jul 31, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about CRISPR Therapeutics AG - Common Shares

< Previous 1 2 3 4 5 6 7 8 9

...

36 37 Next >

2 Beaten-Down Stocks With Incredible Upside Potential ↗

April 30, 2025

Via The Motley Fool

5 Monster Stocks -- Such as Coupang -- to Hold for the Next 10 Years ↗

April 20, 2025

Via The Motley Fool

Topics Artificial Intelligence Economy

3 Magnificent Stocks That Could Double or More by 2030 ↗

April 12, 2025

Via The Motley Fool

Could CRISPR Therapeutics Become the Next Vertex Pharmaceuticals? ↗

April 11, 2025

Via The Motley Fool

4 Beaten-Down Stocks That Could Skyrocket by 50% to 543%, According to Wall Street ↗

April 07, 2025

Via The Motley Fool

Prediction: CRISPR Therapeutics Will Beat the Market. Here's Why ↗

February 28, 2025

Via The Motley Fool

Market Whales and Their Recent Bets on CRSP Options ↗

February 20, 2025

Via Benzinga

Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought ↗

April 07, 2025

The iconic growth investor made some interesting moves during Friday's market pullback.

Via The Motley Fool

Cathie Wood's Ark Invest Loads Up On Amazon, Coinbase: Offloads UiPath, Roblox ↗

April 04, 2025

Via Benzinga

Why Biotech Stocks Such as Biohaven, Recursion Pharmaceuticals, and CRISPR Therapeutics Plunged in March ↗

April 03, 2025

Via The Motley Fool

Topics Bankruptcy Economy World Trade

Why Biotech Stocks Like Recursion Pharmaceuticals, CRISPR Therapeutics, and Summit Therapeutics Plunged Today ↗

March 31, 2025

Via The Motley Fool

Topics Government World Trade

Moderna, Vaxcyte, Novavax Hammered After Key FDA Official Peter Marks Resigns ↗

March 31, 2025

Peter Marks heads up the department in charge of reviewing vaccines, genetic medicines and cell therapies.

Via Investor's Business Daily

The Future of Healthcare: 10 Predictions For The Next Decade

March 27, 2025

The healthcare industry stands on the brink of a transformative decade, driven by rapid advancements in technology, shifting demographics, and evolving patient expectations. Over the next ten years, we...

Via MarketMinute

Topics Artificial Intelligence

2 Beaten-Down Stocks to Buy on the Dip ↗

March 22, 2025

Via The Motley Fool

2 No-Brainer Biotech Stocks to Buy Right Now ↗

March 19, 2025

Via The Motley Fool

Cathie Wood Stands By Tesla's $2,600 Price Target Despite 40% Stock Drop: 'It's Winner Take Most ↗

March 15, 2025

Via Benzinga

Cathie Wood's Ark Invest Continues To Load Up On Tempus AI, Dumps Bitcoin-Focused Block In Tech Meltdown Aftermath ↗

March 11, 2025

On Tuesday, Cathie Wood‘s Ark Invest executed notable trades, including significant activity involving Tempus AI Inc. (NASDAQ:TEM), Block Inc. (NYSE:XYZ), and DraftKings Inc.<

Via Benzinga

Topics Artificial Intelligence

3 Beaten-Down Biotech Stocks to Buy Before They Soar. Wall Street Is Predicting Jumps of 68% to 250%. ↗

February 28, 2025

Via The Motley Fool

2 Beaten-Down Stocks to Buy Before They Soar by 66% and 415%, According to Wall Street ↗

February 24, 2025

Via The Motley Fool

This Bath & Body Works Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday ↗

February 18, 2025

Via Benzinga

WeRide, CRISPR And GeneDx Are Among Top 10 Mid-Cap Gainers Last Week (Feb 10-Feb 14): Are The Others In Your Portfolio? ↗

February 16, 2025

Top performing mid-cap stocks last week: WRD (+97.62%), GDS (+43.45%), SWTX (+42.58%), RXRX (+40.59%), SOC (+39.09%), WGS (+28.23%), VNET (+28.22%), NSP (+25.99%), CRSP (+25.21%), AXSM (+24.01%)

Via Benzinga

This Analog Devices Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday ↗

February 14, 2025

Via Benzinga

This Informatica Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday ↗

February 14, 2025

Via Benzinga

This Roku Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday ↗

February 14, 2025

Via Benzinga

The Ultimate Healthcare Stock to Buy With $500 Right Now ↗

February 14, 2025

Via The Motley Fool

Why CRISPR Therapeutics Stock Was a Massive Winner on Wednesday ↗

February 12, 2025

Via The Motley Fool

Gilead Sciences, Upstart, Mercury General, Confluent And Other Big Stocks Moving Higher On Wednesday ↗

February 12, 2025

Via Benzinga

Vertex Posts 'Another Impressive Quarterly Revenue Beat.' But The Future Remains Uncertain. ↗

February 11, 2025

The company is entering a year of commercial launches. Those aren't guaranteed to put up cystic fibrosis-like numbers.

Via Investor's Business Daily

Investing $1,000 in These 3 Beaten-Down Stocks Could Be a Brilliant Move ↗

February 10, 2025

Via The Motley Fool

Is Vertex Pharmaceuticals a Buy Now That the FDA Approved Its New Pain Drug? ↗

February 02, 2025

Via The Motley Fool

< Previous 1 2 3 4 5 6 7 8 9

...

36 37 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.